Nimesulide, a selective cyclooxygenase-2 inhibitor inhibits telomerase activity by blocking activation of PKB in gastric cancer cell line.
- Author:
Guo-yong HU
1
;
Bao-ping YU
;
Jie-ping YU
;
Zong-xue RAN
;
He-sheng LUO
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; enzymology; pathology; Cell Line, Tumor; Cell Proliferation; drug effects; Cyclooxygenase Inhibitors; pharmacology; Dose-Response Relationship, Drug; Enzyme Activation; drug effects; Humans; Protein-Serine-Threonine Kinases; metabolism; Proto-Oncogene Proteins; metabolism; Proto-Oncogene Proteins c-akt; Stomach Neoplasms; enzymology; pathology; Sulfonamides; pharmacology; Telomerase; metabolism; Time Factors
- From: Chinese Journal of Oncology 2004;26(4):209-212
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effects of nimesulide, a selective COX-2 inhibitor, on cell viability, telomerase and PKB activities in human gastric cancer cell line SGC7901 and to explore its molecular mechanism of selective growth inhibition.
METHODSMTT assay was used to determine cell viability after incubation for 0, 12, 24, and 48 h in different concentrations (0, 25, 50, 100, 200 micro mol/L) of nimesulide and/or okadaic acid (300 nmol/L). Telomerase and protein kinase B (PKB) activities were detected using TRAP PCR-ELISA and nonradioactive IP-kinase assay.
RESULTSNimsulide caused a time and dose-dependent reduction of cell numbers of SGC7901. The telomerase and PKB activities were significantly inhibited, and the inhibition of telomerase activity was partly associated with decrease in PKB activity.
CONCLUSIONSelective COX-2 inhibitor nimesulide inhibits telomerase activity of gastric cancer cells by partly blocking the activation of protein kinase B. The results suggest an additional signaling pathway underlying the anti-cancer effect of COX-2 inhibitor.
